Nkarta (NASDAQ:NKTX) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Nkarta (NASDAQ:NKTX – Free Report) from a sell rating to a hold rating in a research note released on Saturday morning.

NKTX has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nkarta in a research report on Friday, October 31st. Stifel Nicolaus lowered their target price on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Nkarta in a research note on Wednesday, August 13th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $13.25.

Read Our Latest Research Report on NKTX

Nkarta Stock Performance

Shares of NASDAQ:NKTX opened at $1.81 on Friday. The firm’s fifty day moving average is $2.08 and its 200-day moving average is $2.00. The firm has a market cap of $128.56 million, a PE ratio of -1.31 and a beta of 0.80. Nkarta has a 52 week low of $1.31 and a 52 week high of $3.16.

Nkarta (NASDAQ:NKTX – Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.03. Sell-side analysts forecast that Nkarta will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. American Century Companies Inc. grew its stake in shares of Nkarta by 6.5% during the 1st quarter. American Century Companies Inc. now owns 96,838 shares of the company’s stock valued at $178,000 after purchasing an additional 5,886 shares during the period. SG Americas Securities LLC grew its stake in Nkarta by 35.0% during the third quarter. SG Americas Securities LLC now owns 23,663 shares of the company’s stock valued at $49,000 after acquiring an additional 6,141 shares in the last quarter. CWM LLC increased its holdings in shares of Nkarta by 23.4% in the second quarter. CWM LLC now owns 34,758 shares of the company’s stock worth $58,000 after purchasing an additional 6,601 shares during the last quarter. Peapod Lane Capital LLC raised its holdings in shares of Nkarta by 1.1% during the 3rd quarter. Peapod Lane Capital LLC now owns 671,266 shares of the company’s stock worth $1,390,000 after acquiring an additional 7,416 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Nkarta by 4.0% during the second quarter. BNP Paribas Financial Markets now owns 231,081 shares of the company’s stock valued at $384,000 after purchasing an additional 8,968 shares in the last quarter. 80.54% of the stock is owned by institutional investors.

Nkarta Company Profile

(Get Free Report)

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

Further Reading